Ralph Carbone, DO
Interventional Pain Medicine · Mishawaka, INNPI 1447212006
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 494 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 26.7% of the total.
Across 494 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Scilex Pharmaceuticals Inc.$1K
- Collegium Pharmaceutical, Inc.$1K
- Medtronic$748
- Amgen$272
- Abbott$260
- plus $2K from 28 others
What the payments were for
- Food & beverage$7,813100%
- Education$140%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 153 | $2,088 |
| Scilex Pharmaceuticals Inc. | 65 | $1,206 |
| Collegium Pharmaceutical, Inc. | 93 | $1,024 |
| Medtronic(2 entities) | 42 | $748 |
| Amgen | 19 | $272 |
| Abbott | 3 | $260 |
| Teva Pharmaceuticals USA, Inc. | 16 | $210 |
| Pfizer | 10 | $180 |
| Orexo US, Inc. | 9 | $175 |
| Lilly USA, LLC | 7 | $163 |
| Biodelivery Sciences International, Inc. | 10 | $151 |
| Indivior Inc. | 8 | $150 |
| Idorsia Pharmaceuticals US Inc | 2 | $145 |
| Tersera Therapeutics LLC | 5 | $131 |
| Zyla Life Sciences, Inc. | 11 | $123 |
| Corium, LLC | 1 | $113 |
| Boston Scientific | 8 | $108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $107 |
| Almatica Pharma LLC | 4 | $63 |
| AstraZeneca | 5 | $56 |
| Assertio Therapeutics, Inc. | 4 | $44 |
| Redhill Biopharma Inc. | 2 | $43 |
| GRT US Holding, Inc. | 2 | $37 |
| Nevro Corp. | 2 | $35 |
| Hikma Pharmaceuticals USA | 2 | $30 |
| Daiichi Sankyo Inc. | 2 | $23 |
| Alkermes, Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Protega Pharmaceutials Inc | 1 | $18 |
| Vertex | 1 | $18 |
| Bioventus LLC | 1 | $17 |
| Shionogi Inc | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,827 in reported general payments places this provider in the 70th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 200 | $212,016 |
| RelistorMethylnaltrexone Bromide | 68 | $167,103 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $89,522 |
| OxycontinOxycodone Hcl | 38 | $47,898 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 235 | $35,567 |
| BelbucaBuprenorphine Hcl | 47 | $31,921 |
| Oxycodone Hcl | 1,122 | $29,452 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 577 | $21,364 |
| MovantikNaloxegol Oxalate | 29 | $18,762 |
| ZtlidoLidocaine | 15 | $17,686 |
| Fentanyl | 84 | $15,442 |
| Naloxone Hcl | 167 | $7,543 |
| Lidocaine | 34 | $5,231 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 88 | $4,563 |
| Morphine Sulfate ErMorphine Sulfate | 94 | $4,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $1,024 | $243,937247 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $2,088 | $167,10368 claims |
| Endo Pharmaceuticals Inc.Percocet | $12 | $89,52213 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine Hcl, Morphine Sulfate | $30 | $37,948306 claims |
| Redhill Biopharma Inc.Movantik | $43 | $18,76229 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $1,206 | $17,68615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 interventional pain medicine providers in Indiana.
Other interventional pain medicine in Mishawaka
- Ajit PaiMishawaka$6K
- Joshua WellingtonCarmel$315K
- Joseph RutledgeLafayette$96K
- Orlando LandrumElkhart$34K
- Mahendra SanapatiEvansville$31K
- Nikhil ShettyMunster$29K
- David GordonIndianapolis$28K
- Vinayak BelamkarIndianapolis$28K
- Jocelyn BushIndianapolis$20K
- Scott KimGreenwood$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.